JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin

This publication has 20 references indexed in Scilit:

• Specificity of platinum–DNA adduct repair
  Journal of Inorganic Biochemistry, 1999
• Effect of DNA Polymerases and High Mobility Group Protein 1 on the Carrier Ligand Specificity for Translesion Synthesis past Platinum−DNA Adducts
  Biochemistry, 1999
• Combined Cytotoxic Effects of Tumor Necrosis Factor-a with Various Cytotoxic Agents in Tumor Cell Lines That Are Drug Resistant Due to Mutated p53
  Journal of Immunotherapy, 1999
• Cisplatin-induced apoptosis andp53 gene status in a cisplatin-resistant human ovarian carcinoma cell line
  International Journal of Cancer, 1996
• Apoptosis and chemotherapy resistance
  European Journal Of Cancer, 1996
• Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates
  Journal of Pharmaceutical and Biomedical Analysis, 1995
• DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines
  International Journal of Cancer, 1995
• A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration
  Cancer Chemotherapy and Pharmacology, 1995
• An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines
  Biochemical Pharmacology, 1990
• A study of human small‐cell lung carcinoma (hsclc) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (cddp) resistance
  International Journal of Cancer, 1990